Adherence to treatment guidelines in clinical practice for using electroconvulsive therapy in major depressive episode.
Journal of Affective Disorders. 2020-03-01; 264: 318-323
DOI: 10.1016/j.jad.2020.01.004
Lire sur PubMed
1. J Affect Disord. 2020 Mar 1;264:318-323. doi: 10.1016/j.jad.2020.01.004. Epub
2020 Jan 7.
Adherence to treatment guidelines in clinical practice for using
electroconvulsive therapy in major depressive episode.
Samalin L(1), Yrondi A(2), Charpeaud T(3), Genty JB(4), Blanc O(5), Sauvaget
A(6), Stéphan F(7), Walter M(7), Bennabi D(8), Bulteau S(6), Haesebaert F(9),
D’Amato T(9), Poulet E(10), Holtzmann J(11), Richieri RM(12), Attal J(13), Nieto
I(14), El-Hage W(15), Bellivier F(14), Schmitt L(2), Lançon C(12), Bougerol
T(11), Leboyer M(4), Aouizerate B(15), Haffen E(8), Courtet P(16), Llorca PM(5).
Author information:
(1)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; Fondation Fondamental, Créteil, France; Department of
Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne,
Clermont-Ferrand EA 7280, France. Electronic address:
.
(2)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; Fondation Fondamental, Créteil, France; Service de
Psychiatrie et de Psychologie Médicale de l’adulte, CHU de Toulouse, Hôpital
Purpan, ToNIC Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS,
Toulouse, France.
(3)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; Department of Psychiatry, CHU Clermont-Ferrand,
University of Clermont Auvergne, Clermont-Ferrand EA 7280, France.
(4)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; Fondation Fondamental, Créteil, France; University of
Paris-Est, UMR_S955, UPEC, Créteil, France Inserm, U955, Equipe 15 Psychiatrie
génétique, Créteil, France; AP-HP, Hôpital H. Mondor-A. Chenevier, Pôle de
psychiatrie, Créteil, France.
(5)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; Fondation Fondamental, Créteil, France; Department of
Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne,
Clermont-Ferrand EA 7280, France.
(6)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; CHU Nantes, Movement – Interactions – Performance, MIP,
EA 4334, INSERM-U1246 SPHERE University of Nantes and University of Tours,
Nantes, France.
(7)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; Fondation Fondamental, Créteil, France; Service
Hospitalo-Universitaire de Psychiatrie Générale et de Réhabilitation Psycho
Sociale, EA 7479, CHRU de Brest, Hôpital de Bohars, Brest, France.
(8)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; Fondation Fondamental, Créteil, France; Department of
Clinical Psychiatry, CIC-1431 INSERM, CHU de Besançon, EA481 Neurosciences,
University Bourgogne Franche-Comté, Besançon, France.
(9)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; Fondation Fondamental, Créteil, France; Centre
Hospitalier Le Vinatier, Inserm U1028, CNRS UMR5292, Lyon Neuroscience Research
Center, PSY-R2 Team, University Lyon 1, Lyon, France.
(10)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; Fondation Fondamental, Créteil, France; Department of
Emergency Psychiatry, hospices civils de Lyon, Edouard-Herriot Hospital,
Neuroscience Research Center, CNRS UMR5292, PSY-R2 Team, University Lyon, Lyon,
France.
(11)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; Fondation Fondamental, Créteil, France; CHU Grenoble
Alpes, Grenoble Institut Neurosciences, Inserm, U1216, University of Grenoble
Alpes, Grenoble, France.
(12)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; Fondation Fondamental, Créteil, France; Pôle
Psychiatrie, CHU La Conception, Marseille, France.
(13)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; Fondation Fondamental, Créteil, France; University
Department of Adult Psychiatry, La Colombiere Hospital, CHU Montpellier,
University of Montpellier 1, Inserm, Montpellier 1061, France.
(14)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; Fondation Fondamental, Créteil, France; AP-HP, GH
Saint-Louis – Lariboisière – Fernand Widal, Pôle Neurosciences Tête et Cou,
Inserm UMRS 1144, University Paris Diderot, Paris, France 16 UMR 1253, iBrain,
University of Tours, Inserm, Tours, France.
(15)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; Fondation Fondamental, Créteil, France; Department of
General and Academic Psychiatry, CH Charles Perrens, Bordeaux, Laboratory
Nutrition and Integrative Neurobiology (UMR INRA 1286), University of Bordeaux,
Bordeaux, France.
(16)French Society for Biological Psychiatry and Neuropsychopharmacology, Saint
Germain en Laye, France; Fondation Fondamental, Créteil, France; Department of
Emergency Psychiatry and Acute Care, CHU Montpellier, Inserm U1061, Montpellier
University, Montpellier, France.
BACKGROUND: ECT is the most effective treatment of major depressive episode
(MDE) but remains a neglected treatment. The French Society for Biological
Psychiatry and Neuropsychopharmacology aimed to determine whether prescribing
practice of ECT followed guidelines recommendations.
METHODS: This multicenter, retrospective study included adult patients with
major depressive disorder (MDD) or bipolar disorder (BD), who have been treated
with ECT for MDE. Duration of MDE and number of lines of treatment received
before ECT were collected. The reasons for using ECT, specifically first-line
indications (suicidality, urgency, presence of catatonic and psychotic features,
previous ECT response, patient preference) were recorded. Statistical
comparisons between groups used standard statistical tests.
RESULTS: Seven hundred and forty-five individuals were included. The mean
duration of MDE before ECT was 10.1 months and the mean number of lines of
treatment before ECT was 3.4. It was significantly longer for MDD single episode
than recurrent MDD and BD. The presence of first-line indications for using ECT
was significantly associated to shorter duration of MDE (9.1 vs 13.1 months,
p